Your browser doesn't support javascript.
loading
Pharmacological effect of cepharanthine on SARS-CoV-2-induced disease in a Syrian hamster model.
Uematsu, Takayuki; Takai-Todaka, Reiko; Haga, Kei; Kobayashi, Hideyuki; Imajima, Makiko; Kobayashi, Noritada; Katayama, Kazuhiko; Hanaki, Hideaki.
Afiliación
  • Uematsu T; Biomedical Laboratory, Division of Biomedical Research, Kitasato University Medical Center, Arai, Kitamoto, Saitama, Japan. Electronic address: tuematsu@insti.kitasato-u.ac.jp.
  • Takai-Todaka R; Laboratory of Viral Infection Control, Omura Satoshi Memorial Institute, Kitasato University, Tokyo, Japan. Electronic address: todaka@lisci.kitasato-u.ac.jp.
  • Haga K; Laboratory of Viral Infection Control, Omura Satoshi Memorial Institute, Kitasato University, Tokyo, Japan. Electronic address: khaga@lisci.kitasato-u.ac.jp.
  • Kobayashi H; Tokyo New Drug Research Laboratories, Pharmaceutical Business Unit, Kowa Company, Ltd., Tokyo, Japan. Electronic address: air-macaron@a.email.ne.jp.
  • Imajima M; Tokyo New Drug Research Laboratories, Pharmaceutical Business Unit, Kowa Company, Ltd., Tokyo, Japan. Electronic address: mkwatanb@kowa.co.jp.
  • Kobayashi N; Biomedical Laboratory, Division of Biomedical Research, Kitasato University Medical Center, Arai, Kitamoto, Saitama, Japan. Electronic address: kenchu@insti.kitasato-u.ac.jp.
  • Katayama K; Laboratory of Viral Infection Control, Omura Satoshi Memorial Institute, Kitasato University, Tokyo, Japan. Electronic address: katayama@lisci.kitasato-u.ac.jp.
  • Hanaki H; Infection Control Research Center, Omura Satoshi Memorial Institute, Kitasato University, Tokyo, Japan. Electronic address: hanaki@insti.kitasato-u.ac.jp.
J Infect Chemother ; 2024 Aug 27.
Article en En | MEDLINE | ID: mdl-39197667
ABSTRACT

BACKGROUND:

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), remains a global public health threat. Although several effective vaccines and therapeutics have been developed, continuous emergence of new variants necessitates development of drugs with different mechanisms of action. Recent studies indicate that cepharanthine, a chemical derivative purified from Stephania cepharantha, inhibits SARS-CoV-2 replication in vitro.

METHODS:

This study examined the in vivo effects of cepharanthine using a Syrian hamster SARS-CoV-2 infection model. To evaluate the prophylactic and therapeutic effects, cepharanthine was intranasally administered before or after SARS-CoV-2 infection. Effects were assessed by monitoring body weight changes, lung pathology, lung viral load, and inflammatory response in the lungs.

RESULTS:

Pre-infection administration of cepharanthine resulted in less weight loss, reduced virus titers, alleviated histopathological severity, and decreased lung inflammation. Furthermore, post-infection administration of cepharanthine also exhibited therapeutic effects.

CONCLUSIONS:

This study demonstrated that both prophylactic and therapeutic administration of cepharanthine reduces the pathogenesis of COVID-19 in a Syrian hamster SARS-CoV-2 infection model. Our findings suggest that cepharanthine is a potential therapeutic agent against COVID-19.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Infect Chemother Asunto de la revista: MICROBIOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2024 Tipo del documento: Article Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Infect Chemother Asunto de la revista: MICROBIOLOGIA / TERAPIA POR MEDICAMENTOS Año: 2024 Tipo del documento: Article Pais de publicación: Países Bajos